 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes THIOTHIXENE increase or decrease the risk of hospitalization?[0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes THIOTHIXENE increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"thiothixene"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: THIOTHIXENE: dosage_and_administration: DOSAGE AND ADMINISTRATION Dosage of thiothixene capsules should be individually adjusted depending on the chronicity and severity of the symptoms of [0m
[31mschizophrenia. In general, small doses should be used initially and gradually increased to the optimal effective level, based on patient response. Some patients have been successfully maintained on [0m
[31monce-a-day thiothixene capsules therapy. The use of thiothixene capsules in children under [0m[1;31m12[0m[31m years of age is not recommended because safe conditions for its use have not been established. In milder [0m
[31mconditions, an initial dose of [0m[1;31m2[0m[31m mg three times daily is recommended. If indicated, a subsequent increase to [0m[1;31m15[0m[31m mg/day total daily dose is often effective. In more severe conditions, an initial dose [0m
[31mof [0m[1;31m5[0m[31m mg twice daily is recommended. The usual optimal dose is [0m[1;31m20[0m[31m mg to [0m[1;31m30[0m[31m mg daily. If indicated, an increase to [0m[1;31m60[0m[31m mg/day total daily dose is often effective. THIOTHIXENE: dosage_and_administration: [0m
[31mExceeding a total daily dose of [0m[1;31m60[0m[31m mg rarely increases the beneficial response.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: openfda: spl_set_id         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: description: Each Thiothixene Capsules, USP contains [0m[1;31m1[0m[31m mg, [0m[1;31m2[0m[31m mg, [0m[1;31m5[0m[31m mg or [0m[1;31m10[0m[31m mg of thiothixene, USP and the following inactive ingredients: colloidal silicon dioxide, [0m
[31mcroscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch and sodium lauryl sulfate. Each empty hard gelatin capsule contains gelatin, iron [0m
[31moxide red, iron oxide yellow, purified water and titanium dioxide. In addition, the [0m[1;31m1[0m[31m mg hard gelatin capsule contains D&C yellow [0m[1;31m10[0m[31m, FD&C blue [0m[1;31m1[0m[31m and FD&C red [0m[1;31m40[0m[31m. The [0m[1;31m2[0m[31m mg hard gelatin capsule also [0m
[31mcontains D&C yellow [0m[1;31m10[0m[31m and ferrosoferric oxide. The [0m[1;31m5[0m[31m mg and [0m[1;31m10[0m[31m mg hard gelatin capsule also contains ferrosoferric oxide. THIOTHIXENE: description: The capsule is imprinted with black pharmaceutical [0m
[31mink which contains ferrosoferric oxide, potassium hydroxide, propylene glycol and shellac. THIOTHIXENE: description: structure         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: openfda: package_ndc         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: openfda: spl_id         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: openfda: product_ndc         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: warnings: Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m has been reported in association [0m
[31mwith antipsychotic drugs, including thiothixene [0m[1;31m2[0m[31m . Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability [0m[1;31m([0m[31mirregular pulse or [0m
[31mblood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias[0m[1;31m)[0m[31m. The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify [0m
[31mcases where the clinical presentation includes both serious medical illness [0m[1;31m([0m[31me.g., pneumonia, systemic infection, etc.[0m[1;31m)[0m[31m and untreated or inadequately treated extrapyramidal signs and symptoms [0m[1;31m([0m[31mEPS[0m[1;31m)[0m[31m. [0m
[31mOther important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system [0m[1;31m([0m[31mCNS[0m[1;31m)[0m[31m pathology. THIOTHIXENE: [0m
[31mwarnings: The management of NMS should include [0m[1;31m1[0m[1;31m)[0m[31m immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, [0m[1;31m2[0m[1;31m)[0m[31m intensive symptomatic treatment and medical [0m
[31mmonitoring, and [0m[1;31m3[0m[1;31m)[0m[31m treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens [0m
[31mfor uncomplicated NMS. If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be [0m
[31mcarefully monitored, since recurrences of NMS have been reported. Pregnancy Safe use of thiothixene during pregnancy has not been established. Therefore, this drug should be given to pregnant patients[0m
[31monly when, in the judgment of the physician, the expected benefits from the treatment exceed the possible risks to mother and fetus. THIOTHIXENE: warnings: Non-teratogenic Effects Neonates exposed to [0m
[31mantipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, [0m
[31mtremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases [0m
[31mneonates have required intensive care unit support and prolonged hospitalization. Thiothixene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. [0m
[31mAnimal reproduction studies and clinical experience to date have not demonstrated any teratogenic effects. In the animal reproduction studies with thiothixene, there was some decrease in conception [0m
[31mrate and litter size, and an increase in resorption rate in rats and rabbits. Similar findings have been reported with other psychotropic agents. THIOTHIXENE: warnings: After repeated oral [0m
[31madministration of thiothixene to rats [0m[1;31m([0m[1;31m5[0m[31m to [0m[1;31m15[0m[31m mg/kg/day[0m[1;31m)[0m[31m, rabbits [0m[1;31m([0m[1;31m3[0m[31m to [0m[1;31m50[0m[31m mg/kg/day[0m[1;31m)[0m[31m, and monkeys [0m[1;31m([0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/day[0m[1;31m)[0m[31m before and during gestation, no teratogenic effects were seen. Usage in Children [0m
[31mThe use of thiothixene in children under [0m[1;31m12[0m[31m years of age is not recommended because safe conditions for its use have not been established. As is true with many CNS drugs, thiothixene may impair the [0m
[31mmental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, especially during the first few days of therapy. Therefore, [0m
[31mthe patient should be cautioned accordingly. As in the case of other CNS-acting drugs, patients receiving thiothixene should be cautioned about the possible additive effects [0m[1;31m([0m[31mwhich may include [0m
[31mhypotension[0m[1;31m)[0m[31m with CNS depressants and with alcohol.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: precautions: Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the [0m
[31mprescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been [0m
[31mreported, the clinical significance of elevated serum prolactin levels is unknown for most patients. An increase in mammary neoplasms has been found in rodents after chronic administration of [0m
[31mantipsychotic drugs. Neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; [0m
[31mthe available evidence is considered too limited to be conclusive at this time. THIOTHIXENE: precautions: Leukopenia, Neutropenia and Agranulocytosis Class Effect In clinical trial and/or [0m
[31mpostmarketing experience, events of leukopenia/neutropenia and agranulocytosis have been reported temporally related to antipsychotic agents. Possible risk factors for leukopenia/neutropenia include [0m
[31mpreexisting low white blood cell count [0m[1;31m([0m[31mWBC[0m[1;31m)[0m[31m and history of drug induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia [0m
[31mshould have their complete blood count [0m[1;31m([0m[31mCBC[0m[1;31m)[0m[31m monitored frequently during the first few months of therapy and discontinuation of thiothixene should be considered at the first sign of a clinically [0m
[31msignificant decline in WBC in the absence of other causative factors. Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection [0m
[31mand treated promptly if such symptoms or signs occur. THIOTHIXENE: precautions: Patients with severe neutropenia [0m[1;31m([0m[31mabsolute neutrophil count < [0m[1;31m1000[0m[31m/mm [0m[1;31m3[0m[31m [0m[1;31m)[0m[31m should discontinue thiothixene and have their [0m
[31mWBC followed until recovery. Information for Patients Given the likelihood that some patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in [0m
[31mwhom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical [0m
[31mcircumstances and the competency of the patient to understand the information provided. Drug Interactions Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly [0m
[31mincrease the clearance of thiothixene. Patients receiving these drugs should be observed for signs of reduced thiothixene effectiveness [0m[1;31m4[0m[31m,[0m[1;31m5[0m[31m . THIOTHIXENE: precautions: Due to a possible additive [0m
[31meffect with hypotensive agents, patients receiving these drugs should be observed closely for signs of excessive hypotension when thiothixene is added to their drug regimen [0m[1;31m6[0m[31m .         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: warnings: WARNINGS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are [0m
[31mat an increased risk of death. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee BOXED WARNING [0m[1;31m)[0m[31m. Tardive Dyskinesia Tardive dyskinesia, a syndrome [0m
[31mconsisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs, including thiothixene [0m[1;31m1[0m[31m . Although the prevalence of the syndrome [0m
[31mappears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely[0m
[31mto develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown. THIOTHIXENE: warnings: Both the risk of developing the syndrome and the [0m
[31mlikelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, [0m
[31mthe syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. There is no known treatment for established cases of tardive dyskinesia, although the [0m
[31msyndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress [0m[1;31m([0m[31mor partially suppress[0m[1;31m)[0m[31m the signs and symptoms of the [0m
[31msyndrome and thereby may possibly mask the underlying disease process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, [0m
[31mantipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. THIOTHIXENE: warnings: Chronic antipsychotic treatment should generally be [0m
[31mreserved for patients who suffer from a chronic illness that, [0m[1;31m1[0m[1;31m)[0m[31m is known to respond to antipsychotic drugs, and [0m[1;31m2[0m[1;31m)[0m[31m for whom alternative, equally effective, but potentially less harmful treatments are[0m
[31mnot available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The [0m
[31mneed for continued treatment should be reassessed periodically. If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, [0m
[31msome patients may require treatment despite the presence of the syndrome. [0m[1;31m([0m[31mFor further information about the description of tardive dyskinesia and its clinical detection, please refer to â€œ Information[0m
[31mfor Patients â€ in the PRECAUTIONS section, and to the ADVERSE REACTIONS section.         [0m
[31mSOURCE:THIOTHIXENE label[0m


[31mCONTENT: THIOTHIXENE: boxed_warning: WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs [0m
[31mare at an increased risk of death. Analyses of seventeen placebo-controlled trials [0m[1;31m([0m[31mmodal duration of [0m[1;31m10[0m[31m weeks[0m[1;31m)[0m[31m, largely in patients taking atypical antipsychotic drugs, revealed a risk of death in [0m
[31mdrug-treated patients of between [0m[1;31m1.6[0m[31m to [0m[1;31m1.7[0m[31m times the risk of death in placebo-treated patients. Over the course of a typical [0m[1;31m10[0m[31m-week controlled trial, the rate of death in drug-treated patients was [0m
[31mabout [0m[1;31m4.5[0m[31m%, compared to a rate of about [0m[1;31m2.6[0m[31m% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular [0m[1;31m([0m[31me.g., heart failure, sudden death[0m[1;31m)[0m
[31mor infectious [0m[1;31m([0m[31me.g., pneumonia[0m[1;31m)[0m[31m in nature. THIOTHIXENE: boxed_warning: Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may [0m
[31mincrease mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some [0m[1;31mcharacteristic[0m[1;31m([0m[31ms[0m[1;31m)[0m[31m of the patients is[0m
[31mnot clear. Thiothixene is not approved for the treatment of patients with dementia-related psychosis [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:THIOTHIXENE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the THIOTHIXENE label does not directly address the risk of hospitalization due to thiothixene use. However, it does mention that elderly patients with [0m
[32mdementia-related psychosis treated with antipsychotic drugs, including thiothixene, are at an increased risk of death. Additionally, the label includes warnings about Neuroleptic Malignant Syndrome [0m
[1;32m([0m[32mNMS[0m[1;32m)[0m[32m, a potentially fatal symptom complex, and other serious side effects that could potentially lead to hospitalization if not managed properly.[0m

[32mSOURCE: THIOTHIXENE label[0m
[32mEXTRACT_START_END: WARNING Increased Mortality[0m[32m...[0m[32m with dementia-related psychosis [0m[1;32m([0m[32msee WARNINGS [0m[1;32m)[0m[32m.[0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the THIOTHIXENE label does not [0m
[34mdirectly address the risk of hospitalization due to thiothixene use. However, it does mention that elderly patients with dementia-related psychosis treated with antipsychotic drugs, including [0m
[34mthiothixene, are at an increased risk of death. Additionally, the label includes warnings about Neuroleptic Malignant Syndrome [0m[1;34m([0m[34mNMS[0m[1;34m)[0m[34m, a potentially fatal symptom complex, and other serious side [0m
[34meffects that could potentially lead to hospitalization if not managed properly.[0m

[34mSOURCE: THIOTHIXENE label[0m
[34mEXTRACT_START_END: WARNING Increased Mortality[0m[34m...[0m[34m with dementia-related psychosis [0m[1;34m([0m[34msee WARNINGS [0m[1;34m)[0m[34m.[0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDA label for THIOTHIXENE does not directly address the risk of [0m
[32mhospitalization due to thiothixene use. However, it does mention that elderly patients with dementia-related psychosis treated with antipsychotic drugs, including thiothixene, are at an increased risk[0m
[32mof death. Additionally, the label includes warnings about Neuroleptic Malignant Syndrome [0m[1;32m([0m[32mNMS[0m[1;32m)[0m[32m, a potentially fatal symptom complex, and other serious side effects that could potentially lead to [0m
[32mhospitalization if not managed properly.[0m

[32mGiven this information, while the label does not explicitly state an increased risk of hospitalization, the serious side effects and increased risk of death in certain populations imply that there may[0m
[32mbe scenarios where thiothixene use could lead to hospitalization. However, without specific data on the frequency of hospitalization as a side effect, we cannot conclusively say that thiothixene [0m
[32mincreases the risk of hospitalization in general. The risk may be more pronounced in certain populations, such as elderly patients with dementia-related psychosis.[0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does THIOTHIXENE increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if THIOTHIXENE increases or decreases the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the THIOTHIXENE label does not directly address the risk of hospitalization. However, it mentions increased risk of death in elderly patients with dementia-related [0m
[32mpsychosis and warnings about potentially fatal side effects like Neuroleptic Malignant Syndrome [0m[32m([0m[32mNMS[0m[32m)[0m[32m."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for THIOTHIXENE does not provide specific information on the risk of hospitalization associated with its use. While there are serious side effects mentioned that could [0m
[32mpotentially lead to hospitalization, there is no explicit data on the frequency or risk of hospitalization as a side effect. Therefore, we cannot conclusively determine whether THIOTHIXENE increases [0m
[32mor decreases the risk of hospitalization based on the available FDA label information."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does THIOTHIXENE increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if THIOTHIXENE increases or decreases the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the THIOTHIXENE label does not directly address the risk of hospitalization. However, it mentions increased risk of death in elderly patients with dementia-related [0m
[34mpsychosis and warnings about potentially fatal side effects like Neuroleptic Malignant Syndrome [0m[34m([0m[34mNMS[0m[34m)[0m[34m."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for THIOTHIXENE does not provide specific information on the risk of hospitalization associated with its use. While there are serious side effects mentioned that could [0m
[34mpotentially lead to hospitalization, there is no explicit data on the frequency or risk of hospitalization as a side effect. Therefore, we cannot conclusively determine whether THIOTHIXENE increases [0m
[34mor decreases the risk of hospitalization based on the available FDA label information."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does THIOTHIXENE increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if THIOTHIXENE increases or decreases the risk of hospitalization.[0m
[1;31m2[0m[31m. FDAHandler responded that the THIOTHIXENE label does not directly address the risk of hospitalization. However, it mentions increased risk of death in elderly patients with dementia-related [0m
[31mpsychosis and warnings about potentially fatal side effects like Neuroleptic Malignant Syndrome [0m[1;31m([0m[31mNMS[0m[1;31m)[0m[31m.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for THIOTHIXENE does not provide specific information on the risk of hospitalization associated with its use. While there are serious side effects mentioned that [0m
[31mcould potentially lead to hospitalization, there is no explicit data on the frequency or risk of hospitalization as a side effect. Therefore, we cannot conclusively determine whether THIOTHIXENE [0m
[31mincreases or decreases the risk of hospitalization based on the available FDA label information.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-THIOTHIXENE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for THIOTHIXENE does not provide specific information on the risk of hospitalization associated with its use. While there are serious side effects mentioned that could potentially lead [0m
[32mto hospitalization, such as an increased risk of death in elderly patients with dementia-related psychosis and warnings about potentially fatal side effects like Neuroleptic Malignant Syndrome [0m[1;32m([0m[32mNMS[0m[1;32m)[0m[32m, [0m
[32mthere is no explicit data on the frequency or risk of hospitalization as a side effect. Therefore, we cannot conclusively determine whether THIOTHIXENE increases or decreases the risk of [0m
[32mhospitalization based on the available FDA label information.[0m
